

May 23, 2016

CURRICULUM VITAE
WILLIAM MARSHALL SIKOV, M.D., FACP

Primary Business Address: Women and Infants Hospital
Breast Health Center
101 Dudley Street
Providence, RI 02905
Telephone Number: 401-453-7540
Fax Number: 401-453-7785
Email: wsikov@wihri.org

CURRENT POSITION Associate Director of Clinical Research, Program in Women's
Oncology, Women and Infants Hospital of Rhode Island

EDUCATION

Undergraduate: 1974-1978 Brown University, Providence, Rhode Island, Russian
Studies, A.B., 1978, magna cum laude
Medical School: 1978-1982 Yale University School of Medicine, New Haven, CT,
M.D., 1982

POSTGRADUATE TRAINING

Internship and Residency: Internal Medicine, Hospitals, University Health Center, Pittsburgh,
PA - Dr. G. Levey, Director. 1982-1985
Fellowship: Hematology-Oncology, New England Medical Center, Boston,
MA - Dr. R. Schwartz, Director. 1986-1989

PROFESSIONAL LICENSES AND BOARD CERTIFICATIONS

LICENSURE:

1983 Pennsylvania-MD-029919-E
1986 Massachusetts-#56396
1989 Rhode Island-MD 7581

CERTIFICATION:

1985 Internal Medicine 9/85 - ABIM #105940
1988 Hematology - 11/88
1989 Medical Oncology - 11/89

ACADEMIC APPOINTMENTS

2015- Associate Professor of Medicine, Obstetrics and Gynecology
(Clinical), Warren Alpert Medical School of Brown University
2010-2015 Clinical Associate Professor of Medicine, Warren Alpert Medical

1997-2010	School of Brown University Clinical Assistant Professor of Medicine, Brown University School of Medicine
1995-1998	Director, Brown University Combined Hematology-Oncology Fellowship Program
1989-1997	Assistant Professor of Medicine, Brown University School of Medicine

HOSPITAL APPOINTMENTS

2015 -	Active Staff, Memorial Hospital of Rhode Island
2003-	Active Staff, Women and Infants Hospital of Rhode Island
1997-2003	Consulting Staff, Women & Infants Hospital of Rhode Island
2014-	Courtesy Staff, Rhode Island Hospital
1997-2014	Active Staff, Rhode Island Hospital
2014-	Courtesy Staff, Miriam Hospital
1989-2014	Active Staff, Miriam Hospital

OTHER APPOINTMENTS

2015-	NRG Oncology, Breast Working Group
2013-2014	2014 Breast Symposium, Immediate Past Co-Chair, Planning Committee
2012-	Invited author, UpToDate, Breast Cancer section
2012-2013	2013 Breast Symposium, Co-Chair of Planning Committee
2012-2016	National Consortium of Breast Centers, Annual Conference Committee Chair, Abstracts/Posters Committee
2011-2012	2012 Breast Symposium, Co-Chair Elect of Planning Committee
2010-	National Consortium of Breast Centers, Board of Trustees
2010-2011	2011 Breast Symposium, Planning Committee
2010-	Member, Breast Cancer Committee, CALGB (as of 2012, Alliance for Clinical Trials in Oncology)
2009-2010	2010 Breast Symposium, Steering Committee and News Planning Team
2009-	National Consortium of Breast Centers, Conference Planning Committee
2009	Chair, Nominating Committee for Executive Board, CALGB
2008-	Associate Chair, BrUOG
2008	Reviewer, Susan G. Komen Foundation, Promise Grants
2007-	Member, Scientific Advisory Board, BrUOG
2006-2009	Elected to Executive Committee, CALGB
2005	Nominating Committee for Executive Board, CALGB
2003-2005	Board of Directors, University Medicine Foundation
2000-2014	Principal Investigator, Rhode Island Hospital, CALGB (as of 2012, Alliance for Clinical Trials in Oncology (Alliance))
2000-2014	Board of Directors, CALGB (as of 2012, Alliance)
1999-2004	Chair, Data Safety Monitoring Board, Brown University Oncology

Group (BrUOG)
 1999-2000 Editor, Web Alert Feature, Breast Cancer Section, *Current Oncology Reports*
 1995- Chair, Breast Cancer Committee, Brown University Oncology Group
 1995-2000 Responsible Investigator, Miriam Hospital, CALGB

INVITED REVIEWER

Annals of Oncology
 Journal of Clinical Oncology
 Cancer Investigation
 Cancer
 Clinical Breast Cancer
 Lancet
 BMC Cancer

HOSPITAL COMMITTEES (Women and Infants Hospital)

2014- Cancer Control Committee

HOSPITAL COMMITTEES (Miriam or Rhode Island Hospitals)

2009-2014 National Accreditation Program for Breast Center, Breast Program Leadership Committee
 2003-2014 Associate Chair, Clinical Research Review Board, Rhode Island Hospital
 2001-2014 Coordinator, Multidisciplinary Tumor Board
 2005-2014 Coordinator, Multidisciplinary Breast Tumor Board
 2005-2007 Coordinator, Multidisciplinary Thoracic Tumor Board
 1999-2014 Member, Clinical Research Review Board, Rhode Island Hospital
 1996-1998 Member, Lifespan Educational Advisory Committee
 1996-1998 Member, Hospital/PSO Joint Contracting Committee
 1995-2004 Member, Risk Management Committee, Miriam Hospital
 1995 Member, Ad Hoc Committee on Strategies for Maintaining the Jewish Character of the Miriam Hospital
 1994-95 Member, Quality Indicators Steering Committee
 1994-95 Chair, 31-day Readmission Subcommittee
 1989-93, 1996-2015 Member, Cancer Control Committee, Miriam Hospital

UNIVERSITY COMMITTEES

1993-98 Chair, Brown University Hematology-Oncology Fellowship Committee

MEMBERSHIP IN SOCIETIES

2014- NRG Oncology
 2009- National Consortium of Breast Centers
 1989- American College of Physicians
 January 2013 Elected to Fellowship in ACP

1989-	Cancer & Leukemia Group B/Alliance
1989-2014	National Surgical Adjuvant Breast and Bowel Project
1990-	Rhode Island Medical Society
1991-	American Society of Clinical Oncology
1993-	Brown University Oncology Group

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Mark HFL, **Sikov W**, Safran H, King TC, and Griffith RC. Fluorescent in situ hybridization for assessing the proportion of cells with trisomy 4 in a patient with acute non-lymphoblastic leukemia. *Ann Clin Lab Science*, 25:330-335, 1995.
2. Clark J, **Sikov W**, Cummings F, Browne M, Akerley W, Wanebo H, Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski J, et al. Phase II study of 5-fluorouracil, leucovorin and azidothymidine in patients with metastatic colorectal cancer. *J Cancer Res Clin Oncol*, 122:554-8, 1996.
3. Safran H, King TP, Choy H, Hesketh P, Wolf B, Altenhein E, **Sikov W**, Rosmarin A, Akerley W, Radie-Keane K, Ciccetti G. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. *J Clin Oncol*, 15:901-907, 1997.
4. **Sikov WM**, Safran H. Weekly paclitaxel as a radiation sensitizer for locally advanced gastric and pancreatic cancers: The Brown University Oncology Group experience. *Frontiers in Bioscience*, 2:e21-27, 1997.
5. Mark HFL, Pryzogoda JJ, **Sikov W**. Fluorescent in situ hybridization for identifying cytogenetic abnormalities in inadequate and suboptimal specimens. *Pathobiology* 66:216-220, 1998.
6. Mark HF, Gray Y, Mark Y, Khorsand J, **Sikov W**. A multimodal approach in the diagnosis of patients with hematopoietic disorders. *Cancer Gen Cytogen* 109:14-20, 1999.
7. Lopez FF, Sweeney JD, Blair AJ, **Sikov WM**. Spontaneous venous thrombosis in a young patient with combined factor V Leiden and lupus anticoagulant. *Am J Hemat* 62:58-60, 1999.
8. Warkentin TE, **Sikov WM**, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. *Am J Hemat* 62:44-8, 1999.
9. **Sikov WM**, Schiffman FJ, Weaver M, Dyckman J, Shulman R, Torgan P. Splenosis presenting as occult gastrointestinal bleeding. *Am J Hemat* 65:56-61, 2000.
10. Akerley W, Rathore R, Ready N, Leone L, **Sikov W**, Safran H, Kennedy T. A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. *Cancer* 95:2000-5, 2002.
11. Pinto BM, Trunzo JJ, Rabin C, Cady B, Fenton MA, Herman A, Legare R, **Sikov W**.

Recruitment strategies for a home-based physical activity intervention for breast cancer patients. *Journal of Clinical Psychology in Medical Settings* 11: 171-178, 2004.

12. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, **Sikov WM**, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared to every-3-week paclitaxel. *J Clin Oncol* 23: 5983-5992, 2005.
13. Lamont EB, Herndon II JE, Weeks JC,**Sikov W**, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. *J Natl Cancer Inst* 97:1080-1083, 2005.
14. Berz D, **Sikov W**, Colvin G, Weitzen S. 'Weighing in' on screening mammography. *Breast Cancer Res Treat.* 114:569-74, 2009.
15. **Sikov WM**, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA Fenton MA. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group study. *J Clin Oncol* 27: 4693-4700, 2009.
16. Schwarz D, Jue C, **Sikov W**. Primary systemic amyloidosis and persistent pleural effusions. *Amyloid* 16: 239-42, 2009.
17. Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M., Klipfel A, Cataldo T, **Sikov W**, McNulty B, Shipley J, Anderson E, Khurshid H, Oconnor B, Oldenburg N, Radie-Keane K, Husain S, Safran H. Neoadjuvant bevacizumab, oxaliplatin and 5-fluorouracil and radiation for rectal cancer. *Int J Rad Oncol Biol Physics* 82:124-129, 2010.
16. Shapiro C, Halabi S, Hars V, Weckstein D, Kirshner J, **Sikov WM**, Winer EP, Burstein HJ, Hudis CA, Isaacs C, Schilsky RL Paskett ED. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. *Eur J Cancer* 47:683-9, 2011.
17. Reagan JL, Rosmarin A, Butera JN, Nadeem A, Schiffman FJ, **Sikov WM**, Winer E, Mega AE. Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. *Cancer Chemotherapy & Pharmacology.* 68:1075-80, 2011.
18. Merriam P, **Sikov WM**. Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. *Breast Cancer: Targets and Therapy* 3:139-50, 2011.
19. Reeder-Hayes K, Carey L, **Sikov W**. Clinical trials in triple negative breast cancer. *Breast Dis.* 32:123-36, 2012.
20. **Sikov WM**. Neoadjuvant therapy for triple-negative breast cancer: the challenge of

translating biological concepts into effective treatments. *Curr Breast Cancer Rep* 4: 240-248, 2012.

21. Olszewski AJ, Migdady Y, Boolbol SK, Klein P, Boachie-Adjei K, Sakr BJ, **Sikov W**, Shao T. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. *Breast Cancer Res Treat* 138: 215-223, 2013.
22. Cheng H, Bai Y, **Sikov W**, Sinclair N, Bossuyt V, Abu-Khalaf M, Harris L, Rimm D. Quantitative measurements of HER2 and phosphor-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. *BMC Cancer* 14: 326, 2014.
23. Kern P, Kalisch A, Kolberg R, Otterbach F, von Minckwitz G, **Sikov WM**, Pott D, Kurbacher C. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response. *Chemotherapy* 59:387-94, 2013.
24. **Sikov WM**, Berry DA, Perou CP, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in Stage II-III triple-negative breast cancer: CALGB 40603 (Alliance). *J Clin Oncol* 33:13-21, 2015. PMID: 25092775
*This article was selected as one of seven 'Best of JCO 2015' articles for re-publication and distribution at the 2015 ASCO Annual Meeting
25. Golshan M, Cirrincione C, **Sikov WM**, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast conserving surgery and breast conservation rates: Surgical results from CALGB 40603 (Alliance). *Ann Surg* 263:434-439, 2015.
26. Ligibel JA, Cirrincione C, Liu M, Citro M, Ingle J, Gradishar W, Martino S, **Sikov W**, Michaelson R, Mardis E, Ellis M, Perou C, Winer EP, Hudis C, Berry D, Barry WT. Body Mass Index, PAM50 subtype and outcomes in node-positive breast cancer patients receiving chemotherapy: CALGB 9741 (Alliance). *J Natl Cancer Inst* 107:9, 2015.
27. Varadan V, Kamalakaran S, Gilmore H . . . **Sikov W**, Dimitrova N, Harris LN. Brief exposure to preoperative bevacizumab reveals a TGF- β signature predictive of response in HER2-negative breast cancers. *Int J Cancer* 138: 3, 2015.

Accepted for publication:

Warner ET, Ballman KV, Strand C,**Sikov, WM**, Partridge AH. Impact of Race, ethnicity and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials

OTHER PUBLICATIONS

1. **Sikov W**. Recent Advances in Medical Oncology 1995-1996., Medicine and Health Rhode Island 79(3):92-99, 1996.
2. Akerley W, **Sikov WM**, Cummings F., Safran H., and Strenger R. Weekly high dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Seminars in Oncology 24 (suppl 12):s12-10-13, 1997.
3. Akerley W, Choy H, Safran H, **Sikov W**, Rege V, Sanbandam S, Wittels E. Weekly paclitaxel in advanced lung cancer: preliminary data from a phase II trial. Seminars in Oncology 24 (suppl 17):s17-87-90, 1997.
4. **Sikov W**. High-Dose Weekly Paclitaxel for the Treatment of Locally Advanced or Metastatic Breast Cancer. Monograph, 1998.
5. Same-day Summaries of the 1998 San Antonio Breast Cancer Symposium, published by Medscape: December 12-15, 1998
Predictive value of HER-2 Confirmed, Status of Other Markers Less Certain
Sentinel Lymph Node Explorations
Approaches to Adjuvant Hormonal, Chemo, and Radiation Therapy
Bisphosphonates in Breast Cancer
New Insights on Tamoxifen Resistance
6. Same-day Summaries of the 1999 San Antonio Breast Cancer Symposium, published by Medscape: December 8-12, 1999
Sentinel Lymph Node Explorations (Again)
Sentinel Lymph Node Sampling: Raising New Questions
Which Breast cancer patients Should Be Treated With Bisphosphonates?
Local Control Issues in *In Situ* and Invasive Breast Cancers
Dose Intensification Remains a Concept to be Proven in Breast Cancer
7. **Sikov WM**, Said BM. Web alert [Directory] Current Oncology Reports. 1(1): 3-4, 1999
8. **Sikov WM**. Locally advanced breast cancer. Current Treatment Options in Oncology. 1:228-238, 2000.
9. **Sikov W**. Preoperative systemic therapy in breast cancer. Medscape CME, March 12, 2010.
10. **Sikov WM**. Neoadjuvant chemotherapy for triple-negative breast cancer: maximizing pathologic complete response rates to improve prognosis. Breast Cancer Symposium 2012 Daily News, expert editorial, September 14, 2012.
11. **Sikov WM**. Why bother offering that clinical trial? An internal dialogue. Breast Cancer Symposium 2013 Daily News, expert editorial, September 7, 2013.

12. **Sikov WM.** General Session IX: Evolving strategies in early stage breast cancer. Breast Cancer Symposium 2013 Proceedings, September 2013.
13. **Sikov WM.** Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting. *Gland Surgery* 3:2014.
14. **Sikov WM.** I'll recommend a clinical trial – if I can. ASCO Education Book, ASCO Annual Meeting, Chicago IL, May 29-June 2, 2015.
15. Kuritzky B, **Sikov WM.** How high a bar to change neoadjuvant therapy for TNBC? *J Comp Eff Res* 4:293-296, 2015.
16. **Sikov WM.** Assessing the role of platinum agents in aggressive breast cancers. *Curr Onc Reports* 17: 3, 2015.

BOOK CHAPTERS (including online)

1. **Sikov WM,** Wolff AC. Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options. UpToDate online, initially published in September 2012, most recently updated September 2014.
2. **Sikov, WM.** Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis. UpToDate online, initially published in November 2012, most recently updated August 2014.

ABSTRACTS

1. Browne MJ, Kennedy T, Cummings F, **Sikov W,** Akerley W, Donehower R, and Clark JW. Phase II Study of Sequential Taxol and Cisplatin for the Treatment of Metastatic Breast Cancer, *Proc Am Soc Clin Oncol*, 14:136, 1995.
2. Clark JW, Beitz J, Cummings F, **Sikov W,** Browne M, Akerley W, Wanebo H, Weitberg AB, Kennedy T, Bigley J, and Darnowski JD. Phase II Study of 5-Fluorouracil (5-FU), Leucovorin (LV) and Azidodeoxythymidine (AZT) in Patients with Metastatic Colorectal Cancer, *Proc Am Soc Clin Oncol* 14:220, 1995.
3. Wehbe T, Akerley W, Sloan L, Safran H, **Sikov W,** Maynard J, Stein B, et al. Strontium-89, Estramustine and Vinblastine (SEV) in Hormone-Refractory Prostate Carcinoma (HRPC): Concurrent Chemoradiotherapy. *Proc Am Soc Clin Oncol*. 15:261, 1996
4. Safran H, King T, Choy H, **Sikov W,** Hesketh P, Wolfe B, Lopez F, Feller E, et al. Phase I Study of Paclitaxel and Concurrent Radiation for Locally Advanced Gastric and Pancreatic Cancer. *Proc Am Soc Clin Oncol*. 15:200, 1996.
5. Safran H, King T, Hesketh P, Tiedman S, **Sikov W,** Kwakwa H, Masko G, et al. Phase II Study of Neoadjuvant Paclitaxel, Cisplatin and Radiation Followed by Esophagectomy for

- Esophageal Carcinoma. Proc Am Soc Clin Oncol. 15:218, 1996.
6. Mega A, Akhtar MS, Safran H, Rich J, **Sikov W**, Flanigan T. Low Dose Weekly Paclitaxel for HIV Associated Kaposi's Sarcoma. Proc Am Soc Clin Oncol. 15:307, 1996.
 7. Badoe K, **Sikov W**. Celiac Disease Masquerading as Dietary Vitamin K Deficiency. Am Coll Phys, RI Chapter Meeting, 1996. (Poster Presentation)
 8. Akerley W, Choy H, Glantz M, Safran H, **Sikov W**, Rege V, Sambandam S, Josephs J, Wittels E. Phase II Trial of Weekly Paclitaxel for Advanced Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol. 16:450, 1997.
 9. Safran H, Gaissert H, Hesketh PJ, Graziano S, Akhtar M, Triedman S, Masko G, Cicchetti C, Koness J, Bogart J, Sambandam S, **Sikov W**, Cole, B, Wanebo H. Neoadjuvant Paclitaxel Cisplatin and Radiation for Esophageal Carcinoma, A Phase II Study. Proc Am Soc Clin Oncol., 16:304, 1997.
 10. Vance M, Aggarwal L, **Sikov W**. Thymoma Presenting with Hemorrhagic Pericardial Effusion in a Patient with Multiple Antibodies. Am Coll Phys., RI Chapter Meeting, 1997. (Poster Presentation)
 11. **Sikov W**, Akerley W, Cummings F, Safran H, Strenger R. High Dose Weekly Paclitaxel for Locally Advanced and Metastatic Breast Cancer. Proc Am Soc Clin Oncol, 16:191, 1997.
 12. Akerley W, Choy H, Glantz M, Safran H, **Sikov W**, Rege V, et al. Weekly Paclitaxel - Marked Activity, Diminished Toxicity and Platelet Stimulating Effect. Lung Cancer 19 (s1):19-20, 1997.
 13. Akerley W, Leone L, Safran H, **Sikov W**, et al. Phase I Trail of Weekly Paclitaxel and Carboplatin. Proc Am Soc Clin Onc 17: 235a (abstract 904), 1998.
 14. **Sikov W**, Akerley W, Cummings F, Strenger R. Weekly High-Dose Paclitaxel Demonstrates Significant Activity in Advanced Breast Cancer. Proc Am Soc Clin Oncol 17: 112a (abstract 432), 1998.
 15. **Sikov WM**, Akerley W, Cummings F, Safran H, Mega A, Strenger R. Weekly High-Dose Paclitaxel in Locally Advanced and Metastatic Breast Cancer. Breast Cancer Research and Treatment 46(1):95, 1997. Poster presentation at 20th Annual San Antonio Breast Cancer Symposium.
 16. Pinto BM, Maruyama MD, Clark M, Feder MS, **Sikov W**, et al. Psychological Changes with Exercise Participation in Breast Cancer Survivors. Proc Int Congress of Behavioral Medicine, 1998.
 17. Kim P, Akerley W, Safran H, Pryzgodka J, Strenger R, **Sikov W**, Rege V, Kennedy T, Legare R. Vinorelbine and Estramustine for Previously Treated, Advanced Breast Cancer. Proc Am

Soc Clin Oncol 18: 113a (abstract 509), 1999.

18. Robinson J, Akerley W, Safran H, Calabresi P, Mega A, **Sikov W**, Fram R, Kennedy T, Leone I. High Dose Weekly Paclitaxel and amifostine (as a Neuroprotectant) for Advanced Non-Small Cell Lung Cancer. Proc Am Soc Clin Oncol 18: 605a (abstract 2337), 1999.
19. **Sikov WM**, Akerley WA, Legare RD, Strenger R. Neoadjuvant high-dose weekly paclitaxel in stage IIB-IIIB breast cancer: A BrUOG study. Br Cancer Res & Treat 57:68 (abstract 249), 1999. Poster presentation at 22th Annual San Antonio Breast Cancer Symposium.
20. Lopez F, **Sikov W**. Phase I studies with weekly docetaxel with Doxil or weekly doxorubicin. Proc Am Soc Clin Oncol 19: 213a (abstract 830), 2000
21. Akerley W, Herndon J, Turrisi A, Graziano S, Williams T, **Sikov W**, Choy H, Watson D, Green M. Induction chemotherapy with paclitaxel and carboplatin followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer: Preliminary analysis of a phase II trial by the CALGB. Proc Am Soc Clin Oncol 19: 490a (abstract 1915), 2000.
22. **Sikov WM**, Hsieh M, Lopez F. Phase I weekly docetaxel with doxorubicin or Doxil: a BrUOG study. Proc Am Soc Clin Oncol 20: 85b (abstract 2008), 2001.
23. **Sikov WM**, Akerley W, Kahanic S, Mangalik A, Arun B, Houston GA, Perry MC, Bertoli L, Kugler J. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel versus standard-dose weekly paclitaxel for metastatic breast cancer. Proc Am Soc Clin Oncol 21: abstract 134, 2002
24. Rathore R, Chougule P, Wanebo H, Nadeem A, Radie-Keane K, **Sikov W**, Negri P, Kennedy T, Reday N. Phase I/II study of induction paclitaxel, ifosfamide and carboplatin followed by chemoradiotherapy in advanced head and neck squamous cell cancers. Proc Am Soc Clin Oncol 23: 511 (abstract 5602), 2004.
25. Ries LM, Fenton MA, Dizon DS, Gass JS, Graves TA, Strenger RS, **Sikov WM**. Neoadjuvant q4week carboplatin and weekly paclitaxel \pm trastuzumab in resectable and locally advanced breast cancer : a Brown University Oncology Group (BrUOG) study. Proc Am Soc Clin Oncol 23: 67s (abstract 759), 2005.
26. **Sikov WM**, Theall KP, Seidler CW, Strenger RS, Fenton MA. Gemcitabine and capecitabine in metastatic breast cancer: a Brown University Oncology Group (BrUOG) study. Proc Am Soc Clin Oncol 23: 74s (abstract 785), 2005.
27. Quddus MR, Kelly D, Steinhoff MM, Sung CJ, Rashid L, Gass J, Strenger R, Legare R, **Sikov W**, Tantravahi U, Dizon DS. Clinical significance of borderline amplification, amplified clones of HER2/neu gene and polysomy 17 in breast cancer patients. 29th Annual San Antonio Breast Cancer Symposium, abstract 2033, December 2006, San Antonio, TX

28. **Sikov WM**, Fenton MA, Strenger R, Dizon DS, Legare RD, Graves TA. Preliminary recurrence and survival analysis of patients receiving neoadjuvant q4week carboplatin and weekly paclitaxel +/- weekly trastuzumab in resectable and locally advanced breast cancer. 30th Annual San Antonio Breast Cancer Symposium, abstract 5063, December 2007, San Antonio, TX
29. **Sikov WM**, Berz D, Colvin G, McCormack E, Weitzen S. "Weighing in" on screening mammography. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 6523)
30. Shapiro CL, Halabi S, Gibson G, Weckstein DJ, Kirshner J, **Sikov WM**, Winer EP, Hudis CA, Isaacs C, Schilsky RL, Paskett E. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 512)
31. Dipetrillo T, Pricolo V, Lagares-Garcia J, **Sikov W**, Vrees M, McNulty B, O'Connor B, Klipfel A, Khurshid H, Safran H. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer. *J Clin Oncol* 27:15s, 2009 (suppl; abstr 4105)
32. Sakr BJ, Dizon DS, Legare R, Gamage M, Wood R, Colvin GA, Constantinou M, Kennedy TA, Fenton MA, **Sikov WM**. Adjuvant therapy after neoadjuvant treatment: Addressing the needs of a high-risk group. 2009 ASCO Breast Symposium, abstract 358.
33. Rizack T, Abu-Khalaf MM, Legare RD, Strenger R, Fenton MA, Sakr BJ, Kennedy TA, Harris L, **Sikov W**. Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, q 3 week carboplatin and targeted agents: interim dose delivery and toxicity data. *J Clin Oncol* 28, 2010 (suppl; abstr e11010)
34. **Sikov WM**, Perou CM, Golshan M, Collyar D, Berry DA, Hahn OM, Singh B, Hudis C, Winer EP, Cancer and Leukemia Group B, North American Intergroup. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. *J Clin Oncol* 28:15s, 2010 (suppl; abstr TPS110)
35. Rizack T, Abu-Khalaf MM, Legare RD, Strenger R, Fenton MA, Sakr BJ, Kennedy TA, Harris L, **Sikov W**. Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, q 3 week carboplatin and targeted agents: interim dose delivery and toxicity data. Warren Alpert Medical School Department of Medicine 16th Annual Research Forum, June 18, 2010, Providence, RI (poster presentation).
36. Sinclair N, Abu-Khalaf MM, Sakr BJ, Rizack T, Lannin DR, Gass JS, Strenger R, Bossuyt V, Fenton MA, Harris L, **Sikov WM**. Carboplatin (Cb), weekly nanoparticle, albumin-bound paclitaxel (wAb), and bevacizumab (Av) neoadjuvant chemotherapy (NAC) in HER2-negative breast cancer (BrCA): A BrUOG study. *J Clin Oncol* 29: 2011 (suppl; abstr e11573)
37. Kamalakaran S, Lezon-Geyda K, Varadan V, Banerjee N, Lannin DR, Rizack T, **Sikov WM**, Abu-Khalaf MM, Janevski A, Harris L. Evaluation of ER/PR and HER2 status by RNA

sequencing in tissue core biopsies from preoperative clinical trial specimens. *J Clin Oncol* 29, 2011 (suppl 27; abstr 46)

38. Varadan V, Kamalakaran S, Janevski A, Banerjee N, Lezon-Geyda K, Bossuyt V, Flowers-Poole D, **Sikov W**, Abu-Khalaf M, Rizack T, Dimitrova N, Harris L. Next generation RNA sequencing reveals changes in gene expression and alternative splicing upon brief exposure to therapy in early breast cancer. *Cancer Res* 2011;71(24 Suppl):Abstract nr P3-06-01.
39. Banerjee N, Kamalakaran S, Vinadan V, Janevski A, Lezon-Geyda K, Bossuyt V, Flowers-Poole D, **Sikov W**, Abu-Khalaf M, Rizack T, Harris L, Dimitrova N. Sno/miRNA expression via next generation sequencing: variation in patients before and after treatment. *Cancer Res* 2011;71(24 Suppl):Abstract nr P3-06-04.
40. Migdady Y, **Sikov WM**, Sakr BJ, Olzwekski AJ. Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer. *J Clin Oncol* 30, 2012 (suppl; abstr 1034).
41. Sinclair NF, Abu-Khalaf MM, Rizack T, Rosati K, Chung G, Legare RD, DiGiovanna M, Fenton MA, Bossuyt V, Strenger R, Sakr BJ, Lannin DR, Gass JS, Harris L, **Sikov WM**. Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study. *J Clin Oncol* 30, 2012 (suppl; abstr 1045)
42. Varadan V, Kamalakaran S, Janevski A, Banerjee N, Lezon-Geyda K, Bossuyt V, Flowers-Poole D, Sinclair NF, Abu-Khalaf MM, **Sikov WM**, Dimitrova N, Harris L. Next-generation RNA sequencing reveals transcriptomic changes after brief exposure to preoperative nab-paclitaxel, bevacizumab, and trastuzumab. *J Clin Oncol* 30, 2012 (suppl; abstr 10508)
43. Varadan V, Kamalakaran S, Janevski A, Banerjee N, Lezon-Geyda K, Miskimen K, Bossuyt V, Abu-Khalaf M, **Sikov W**, Dimitrova N, Harris LN. RNA-Seq Identifies Unique Transcriptomic Changes after Brief Exposure to Preoperative Nab-Paclitaxel (N), Bevacizumab (B) or Trastuzumab (T) and Reveals Down-Regulation of TGF- β Signaling Associated with Response to Bevacizumab. *Cancer Res* PD05-05 (poster discussion)
44. Banerjee N, Maity S, Varadan V, Janevski A, Kamalakaran S, **Sikov W**, Abu-Khalaf M, Bossuyt V, Lannin D, Harris L, Cornfeld D, Dimitrova N. Association of DCE-MRI Texture Features with Molecular Phenotypes and Neoadjuvant Therapy Response in Breast Cancer. *Cancer Res* P4-01-02
45. Shao T, Olszewski AJ, Boolbol SK, Migdady Y, Boachie-Adjei K, Sakr BJ, Klein P, **Sikov W**. Disease-Related Outcomes with Adjuvant Chemotherapy in HER2 Positive or Triple Negative T1a/bN0 Breast Cancers. *Cancer Res* P6-07-34
46. Banerjee N, Varadan V, Kamalakaran S, Janevski A, Miskimen K, Williams N, Abu-Khalaf M, **Sikov W**, Harris LN, Dimitrova N. RNA-seq reveals association of pCR and changes in

- lncRNA expression in pre-operative bevacizumab treatment of breast cancer. AACR 2013, abstract 1828.
47. Varadan V, Miskimen K, Kamalakaran S, Janevski A, Banerjee N, Williams N, Abu-Khalaf M, **Sikov W**, Dimitrova N, Harris L. RNA-seq identifies a TGF- β signature that predicts response to preoperative bevacizumab in breast cancer. AACR 2013, abstract 4566 (oral presentation).
 48. Sinclair NF, Sakr BJ, Abu-Khalaf MM, Somlo G, Black RC, Chung GG, Rizack T, Strenger R, Fenton MA, DiGiovanna M, Constantinou M, Lannin DR, Legare RD, Chagpar AB, Sambandam ST, Bossuyt V, Rosati K, Harris L, **Sikov WM**. Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study. *J Clin Oncol* 31, 2013 (suppl; abstr 619)
 49. Connell NT, **Sikov WM**, Faricy-Anderson KE, Korber S, Thomas AG, Rosati K, Safran H, Mega AE. Assessment of the effectiveness of a chemotherapy education program: A Brown University Oncology Research Group study. *J Clin Oncol* 31, 2013 (suppl; abstr 6574)
 50. Ligibel J, Cirrincione C, Liu MC, Citron ML, Ingle JN, Gradishar WJ, Martino S, **Sikov WM**, Michaelson RA, Hudis C, Winer EP, Barry WT. Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance). *J Clin Oncol* 31, 2013 (suppl; abstr 1032)
 51. Williams N, Varadan V, Vadodkar A, Miskimen K, Gilmore HL, Beckloff N, Edelheit S, Prabhakar D, Janevski A, Banerjee N, Kamalakaran S, Abu-Khalaf MM, **Sikov WM**, Dimitrova N, Harris L. TGF β signature at 2 weeks to predict response to preoperative therapy (PT) with bevacizumab (B) and chemotherapy (CT) in early breast cancer (EBC). *J Clin Oncol* 31, 2013 (suppl; abstr 1046)
 52. **Sikov WM**, Berry DA, Perou CM, Singh B, Cirrincione C, Tolaney S, Kuzma CS, Pluard TJ, Somlo G, Port E, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis C, Winer EP. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance. SABCS 2013, Oral Abstract S05-01
 53. Williams N, Varadan V, Miskimen K, Vadodkar A, Poruban D, Edelheit S, Gilmore H, Maximuk S, Sinclair N, Lezon-Geyda K, Abu-Khalaf M, **Sikov W**, Harris L. Deep sequencing of breast tumor biopsies reveals an association between pathologic complete response and reduction of TP53 clonal abundance upon brief exposure to therapy. SABCS 2013, Poster Abstract P1-08-16.
 54. Banerjee N, Chothani S, Kamalakaran S, Varadan V, Miskimen K, Vadodkar A, Abu-Khalaf M, **Sikov W**, Harris LN, Dimitrova N. RNA-seq reveals functional lncRNAs associated with estrogen-receptor status in breast cancer. SABCS 2013, Poster Abstract P4-04-02.

55. Varadan V, Agrawal V, Kamalakaran S, Banerjee N, Miskimen K, Vadodkar A, Abu-Khalaf M, **Sikov W**, Harris LN, Dimitrova N. Heterogeneous gene fusions detected by RNASeq show enrichment of insulin signaling pathway genes in breast cancer. SABCS 2013, Poster Abstract P4-04-07.
56. Von Minckwitz G, O'Shaughnessy J, Winer EP, Wolmark N, Geyer, Jr CE, Huober J, Loibl S, **Sikov WM**, Untch M, McKee MD, Giranda VL, Rugo H. Phase 3 study evaluating the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in patients with early stage triple-negative breast cancer (TNBC). ASCO 2014 Trials in Progress Poster
57. Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Perez EA, **Sikov WM**, Chennuru S, Mirshahidi H, Vidito S, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer. SABCS 2014, Poster Presentation P3-11-16.
58. **Sikov WM**, Barry WT, Hoadley KA, Pitcher BN, Singh B, Tolaney ST, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Berry DA, Hahn OM, Carey LA, Perou CM, Hudis CA, Winer EP. Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance), SABCS 2014, Oral Abstract Presentation S04-05.
59. Iglesias MD, Vincent BG, Serody JS, Carey LA, Barry WT, **Sikov WM**, Hudis C, Winer EM, Perou CM. Impact of tumor-infiltrating B-cell clonal diversity on response to neoadjuvant therapy in triple-negative and HER2+ breast cancer treated on CALGB (Alliance) 40601 and 40603. SABCS 2014, Poster Discussion PD01-03.
60. Golshan M, Cirrincione CT, Berry DT, Sikov WM, Jasinski S, Weisberg TF, Somlo G, Winer EP, Hudis C, Ollila DW. Impact Of The Addition Of Carboplatin And/or Bevacizumab To Neoadjuvant Paclitaxel Followed By Doxorubicin And Cyclophosphamide On Breast Conservation Rates In Triple-negative Breast Cancer: Surgical Results From CALGB 40603 (Alliance). ASA 2015, Oral Presentation, April 23, 2015.
61. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Somlo G, Port ER, Qamar R, Sturtz K, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)", SABCS 2015, Oral Abstract Presentation S2-05
62. Agrawal V, Varadan V, Parsai S, Banerjee N, Miskimen K, Vadodkar A, Abu-Khlafa M, **Sikov W**, Harris L, Dimitrova N. Novel recurrent lncRNA –gene fusions detected in Breast Cancer using RNA-Seq technology in a neoadjuvant setting", SABCS 2015, Poster Presentation P6-03-08.

INVITED PRESENTATIONS

National Meetings

“Cost-Effective Care of the Breast Cancer Patient: How the Disciplines Can Work Together to Reduce Unnecessary Evaluations and Interventions While Preserving Quality: Moderator and Medical Oncology Perspective”, 26th Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, April 10, 2016

“The Best of the National Meetings: Everything I Need to Know I Learned at NCoBC: Medical Oncology”, 26th Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, April 9, 2016

“Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)”, Oral presentation, 2015 San Antonio Breast Cancer Symposium, San Antonio, TX, December 9, 2015

“Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in 2015”, 25th Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 15, 2015

“Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance)”, Oral presentation, 2014 San Antonio Breast Cancer Symposium, San Antonio, TX, December 11, 2014.

“Preoperative Platinum: A New Standard of Care?”, 13th Annual International Congress on the Future of Breast Cancer, Huntington Beach, CA, July 19, 2014

“Platinums for TNBC – Who, When and How?”, Breast Cancer: New Horizons, Current Controversies, Boston, MA, July 11, 2014

“Neoadjuvant Therapy for Breast Cancer 2014: Current Status, Significant Recent Data, and the Impact of FDA Guidelines on its Future”, 24th Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 18, 2014

“Silent no longer: The medical and emotional issues of living with metastatic breast cancer”, 24th Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 19, 2014

“Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)” Oral presentation, 2013 San Antonio

Breast Cancer Symposium, San Antonio, TX, December 13, 2013.

“Late Complications of Breast Cancer Treatment”, 23rd Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 27, 2013

“Triple Negative Breast Cancer: Basic Concepts”, 22nd Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 12, 2012

“Locally Advanced Breast Cancer: Basic Concepts and Systemic Therapy”, 22nd Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 13, 2012

"Medical Considerations for Breast Cancer in Younger Women", 21st Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 14, 2011

"Neoadjuvant Therapy for Resectable and Locally Advanced Breast Cancer", 21st Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 15, 2011

"PRO/CON: Adjuvant Chemotherapy is Recommended for the Woman with Persistent Disease After Neoadjuvant Chemotherapy", 20th Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, March 22, 2010, Las Vegas, NV

"Multidisciplinary Tumor Board - Demonstration & Interaction", 20th Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 23, 2010

"Should Adjuvant Platinum Be Used in High-Risk Triple-Negative Breast Cancer? Green Light", Ninth International Congress on the Future of Breast Cancer, La Jolla, CA July 24, 2010

"Breast Cancer Tumor Board", 19th Annual National Interdisciplinary Breast Center Conference, National Consortium of Breast Centers, Las Vegas, NV, March 23, 2010
NCBC National Meeting, March 2009, Las Vegas, NV

“Multicenter, 3-Arm Randomized Study of High-Dose Weekly Paclitaxel (HDWP) Versus Standard-Dose Weekly Paclitaxel (SDWP) for Metastatic Breast Cancer (MBC).” Oral presentation, 2002 Annual Meeting of American Society of Clinical Oncology, Orlando, FL - May 19, 2002

International

1. “High-dose Weekly Paclitaxel in Breast Cancer” at The Fox Chase Cancer Center and Free University Hospital Paclitaxel Investigators’ Workshop and Consensus Conference, St. Thomas, U.S. Virgin Islands, March 28, 1998

2. "Weekly Paclitaxel in Neoadjuvant and Metastatic Breast Cancer" at "New Strategies in the Treatment of Breast Cancer" Symposium at the 1st European Breast Cancer Conference, Florence, Italy, September 30, 1998
3. "Recent Advances in the Treatment of Early Stage and Advanced Breast Cancer", National Cancer Center, Tokyo, Japan, March 24, 2003
4. " Overview of Early Breast Cancer: Emerging Trends from Randomized Studies", Latin America Breast Cancer Regional Medical Conference, July 11, 2008, Quito, Ecuador
5. "Predictive Markers/ Patient Selection", Latin America Breast Cancer Regional Medical Conference, July 11, 2008, Quito, Ecuador
6. "Novel Agents in Breast Cancer Therapy and Predictive Markers/Patient Selection", Latin America Breast Cancer Regional Medical Conference, July 11, 2008, Quito, Ecuador
7. "Overview of Early Breast Cancer: Emerging Trends from Randomized Studies", 2009 Women's Cancer Regional Medical Conference, April 17, 2009, Istanbul, Turkey
8. "Integration of Targeted Agents and Chemotherapy", 2009 Women's Cancer Regional Medical Conference, April 17, 2009, Istanbul, Turkey

Local/Regional (2009-2014)

"Personalized Therapy for Breast Cancer - 2009", Alpert Medical School of Brown University Division of Hematology-Oncology Grand Rounds, January 2009, Providence, RI

"What You Need to Know About Breast Cancer" , North Kingstown High School, Rhode Island Cancer Council/Pink Spirit Week, April 2009, North Kingstown, RI

"BrUOG Breast Cancer Neoadjuvant Trials - 1995-2009", University of Massachusetts Oncology Rounds, May 2009, Worcester, MA

"Breast Cancer 2009: Chemotherapy and Beyond", Avenues of Healing, October 6, 2009, Warwick, RI

"Breast Cancer in the Younger Woman: New Treatment Modalities", Oncology Nursing Conference, November 7, 2009, Seekonk, MA

"Breast Cancer Screening: The Mammography Controversy", Annual Scientific Meeting, Rhode Island Chapter, American College of Physicians, Warwick, Rhode Island, May 13, 2010

"Strategies for Successful Accrual to CALGB Neoadjuvant Breast Cancer Trials", CALGB Summer Group Meeting, Chicago, IL, June 24, 2010

"Breast Cancer 2010: Changes in Staging and Recent Advances from ASCO", Medical Grand Rounds, Warren Alpert Medical School of Brown University, August 23, 2010, Providence, RI
"Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer", Hematology-Oncology Grand Rounds, Warren Alpert Medical School of Brown University, October 14, 2010, Providence, RI

"Neoadjuvant Chemotherapy", Advances in Breast Cancer Management, Warren Alpert Medical School of Brown University and Division of Hematology-Oncology, Rhode Island and Miriam Hospitals, November 18, 2010, Providence, RI

GRANTS/RESEARCH SUPPORT

PAST (as Principal Investigator):

1. Breast Cancer Research Foundation Grant for \$250,000 for project entitled "CALGB 40603: Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC/EC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer." October 2008-September 2010, renewed September 2010-
2. Abraxis BioSciences (division of Celgene): Grant for \$520,500 for project entitled "Q3week carboplatin with Weekly Abraxane and trastuzumab as neoadjuvant therapy in resectable and unresectable (stage IIA-III B) HER2+ breast cancer - BrUOG BR-211B -June 2008-May 2014
3. Abraxis BioSciences (division of Celgene): Grant for \$465,500 for project entitled "Q3week carboplatin with weekly Abraxane and Avastin \pm subsequent dose-dense AC with Avastin as neoadjuvant therapy in resectable and unresectable (stage IIA-III B) HER2-negative breast cancer - September 2008-May 2014
4. Cancer and Leukemia Group B and CALGB Foundation (as of 2012, Alliance)
National Cancer Institute
Support based on accrual to CALGB and CTSU trials
1991-2014
5. Co-Investigator NCI (R01 CA101770) (PI: Bernardine Pinto, Ph.D.)
\$1.87 million
Promoting Physical Activity after Colorectal Cancer (2004-2010)
6. Weekly Paclitaxel and q4week Carboplatin \pm Herceptin as neoadjuvant therapy in resectable and unresectable (stage IIA - III B) breast cancer
Bristol Myers-Squibb Oncology
\$200,000
4/15/2003-2008
William M. Sikov and Mary Anne Fenton, PIs

7. Weekly Paclitaxel and q4week Carboplatin ±Herceptin as neoadjuvant therapy in resectable and unresectable (stage IIA - IIIB) breast cancer
Genentech
\$200,000
4/15/2003-2008
William M. Sikov and Mary Anne Fenton, PIs
8. A Phase II Study of Neoadjuvant Bevacizumab, Oxaliplatin, 5-Fluorouracil and Radiation in Clinical Stage II-III Rectal Cancer
Genentech
\$160,000
4/1/2005-2008
Howard Safran and William M. Sikov, PIs
9. A Phase II Study of Neoadjuvant Bevacizumab, Oxaliplatin, 5-Fluorouracil and Radiation in Clinical Stage II-III Rectal Cancer
sanofiAventis
\$160,000
4/1/2005-2008
Howard Safran and William M. Sikov, PIs
10. BrUOG BR-87 - “Gemcitabine and Capecitabine in Advanced Breast Cancer: A BrUOG Phase II Study”
Eli Lilly and Company
\$210,000
11/01-11/04
William M. Sikov, MD, PI
11. Cancer and Leukemia Group B
National Cancer Institute/National Institutes of Health
U10 CA08025-3
\$350,000
4/98-3/03
William M. Sikov, MD, PI
12. BrUOG BR-87 - “Gemcitabine and Capecitabine in Advanced Breast Cancer: A BrUOG Phase II Study”
Roche Pharmaceuticals
\$210,000
11/01-11/04
William M. Sikov, MD, PI

University Teaching Roles

1. Director of Hematology-Oncology Fellowship Program 1995-98 – This involved overseeing

the educational program for an average of 10 fellows each year, including scheduling, evaluations and feedback, and recruiting 3-4 new fellows each year.

2. Hematology-Oncology Key Faculty and Fellowship Selection Committee - 1999- 2014 – To assist the fellowship program director with planning and assessing the educational program, evaluation of current fellows and serving on the interview and selection committee for fellow candidates

3. Hematology-Oncology Fellowship Research Mentoring Committee - 2009-2012 – To meet with each of the current fellows over the course of the year to ensure that they have identified a mentor and are participating in a meaningful way in the division's research

4. 2nd year Medical School pathophysiology course, hematology-oncology section

Small group leader - 1994-6

Lectures on leukemia and myelodysplasia (2 lectures each year to class of ~80)) - 1998-2008, 2011-2013

Lectures on antineoplastic agents (2 lectures each year to class of ~80)) - 2009-2014

5. Preceptor, Affinity Group "Death and Dying", 1998-2002

6. Hematology-Oncology Grand Rounds – 1-2 presentations/year on breast cancer, conference reviews and other topics – 10 fellows and variable numbers of faculty

Hospital Teaching Roles

1. Inpatient service attending with daily teaching rounds for fellows, residents and students – 6 hrs/day, 5 days/week, 2 months/year, 1989-2014

2. Clinic preceptor for fellow's continuity clinic - 4 hrs/day, 1-2 days/week, 48 weeks/yr 1989-2012

3. Nurse practitioner rounds - 2-3 hours/day, 5 days a week, every 8 weeks = 75 hrs/year

4. Director of Breast Tumor Board 2005-2014 and Multidisciplinary Tumor Board 1989-2014, weekly

Teaching Roles effective 8/2014 (transition to WIH Breast Center)

1. Breast Clinic preceptor for Breast and Gyn/Oncs fellows – on average 2 days per week, 4 hours per day

2. Breast Clinic preceptor for Hematology-Oncology fellows from Lifespan rotating thru Breast elective – on average 2-3 days per week, 6 hours per day, 4-6 months per year. They also attend WIH Breast Tumor Board weekly (2 hours/week) during the elective rotation, at which I take a major teaching role.

3. Breast clinic preceptor for residents, medical students and physician assistant students rotating thru Breast Health Center – 1-2 days per week, 4 hours per day.

4. Serve as mentor for Heme-Onc fellows working on clinical trials and concepts to be conducted thru the Brown University Oncology Group – 2 ongoing trials and 1 concept under development (as of July 2015)

Major Research Interests

Treatment of Locally Advanced and Metastatic Breast Cancer

Neoadjuvant Chemotherapy for Breast Cancer

Phase I-II Studies – Drug Delivery and Experimental Therapeutics

Treatment of Early Stage and Advanced Colorectal Cancer